Long-term successful experience of clinical use of systemic isotretinoin (SI) drugs has shown high effectiveness in treating severe and moderate-to-severe forms of acne. The SI dosing regimen in clinical practice is carried out strictly according to the instructions for the drug use and clinical recommendations (daily dose of 0.5—1 mg/kg, course dose of 120—150 mg/kg). SI is taken with food. At the same time, the calculation of daily and cumulative doses for the patient is identical regardless of the presentation form. Peak plasma concentrations (C_max) of isotretinoin increase when taken with food by 1.6 times for lidose-SI and by 2.7 times for standard SI compared to fasting. Thus, the bioavailability of two comparable forms of SI at a single daily dose (40 and 40 mg) is comparable during meal intake. The clinical effectiveness and safety of standard and lidose forms (10 and 20 mg forms) of isotretinoin drugs in identical daily and cumulative doses are comparable. Despite the high effectiveness of SI, the issue of the disease’s relapses and the possibility of their prevention remain relevant. Supportive therapy in acne is the use of appropriate drugs to control the appearance of noninflammatory and inflammatory acne. Systematic review data showed that relapse rate was higher in patients receiving isotretinoin in low-dose treatment setting and intermittent dosing regimen than in high-dose therapy and standard regimens.